Home

The Korea Herald

Latest news

Most Popular

  1. 1

    K-pop group's manager dismissed for setting up spycam in theater dressing room

    K-pop group's manager dismissed for setting up spycam in theater dressing room
  2. 2

    Contentious grain bill put directly to plenary meeting for vote

    Contentious grain bill put directly to plenary meeting for vote
  3. 3

    Why is Apple Pay struggling to get purchase in Korea?

    Why is Apple Pay struggling to get purchase in Korea?
  4. 4

    Will tug-of-war between doctors, government end soon?

    Will tug-of-war between doctors, government end soon?
  5. 5

    Climate impacts set to cut 2050 global GDP by nearly a fifth

    Climate impacts set to cut 2050 global GDP by nearly a fifth
  1. 6

    Trilateral talks acknowledge ‘serious’ slumps of won, yen

    Trilateral talks acknowledge ‘serious’ slumps of won, yen
  2. 7

    [Today’s K-pop] BTS pop-up event to come to Seoul

    [Today’s K-pop] BTS pop-up event to come to Seoul
  3. 8

    [Graphic News] More Koreans say they plan long-distance trips this year

    [Graphic News] More Koreans say they plan long-distance trips this year
  4. 9

    Yoon's approval rating plunges to all-time low

    Yoon's approval rating plunges to all-time low
  5. 10

    Fed: Elevated inflation will likely delay rate cuts this year

    Fed: Elevated inflation will likely delay rate cuts this year
피터빈트

Mundipharma partners with Samsung Bioepis for Hong Kong, Taiwan

By Korea Herald

Published : Jan. 13, 2020 - 16:14

    • Link copied

UK-based Mundipharma said Monday it has secured a partnership with Korea’s Samsung Bioepis to commercialize its first-wave biosimilar candidates in Taiwan and Hong Kong.

The partnership covers Samsung Bioepis’ biosimilar candidates in the field of immunology and oncology, including SB5 (adalimumab), SB4 (etanercept), SB3 (trastuzumab) and SB8 (bevacizumab).


(Yonhap) (Yonhap)

Mundipharma will be the exclusive commercialization partner, while Samsung Bioepis will remain responsible for clinical development, regulatory registration and manufacture of the biosimilars.

“This partnership brings together Samsung Bioepis’ proven biosimilar development platform with Mundipharma’s commercial acumen and market insight and ability to increase patient access to proven treatments,” said Mundipharma CEO Raman Singh in a statement. “This partnership will help to address the patient need in two important territories in Asia for immunology and oncology treatments.” 

(khnews@heraldcorp.com)

More from Headlines